Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and Duke Robotics (NASDAQ:DUKR – Get Free Report) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares Mainz Biomed and Duke Robotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mainz Biomed | N/A | N/A | N/A |
| Duke Robotics | N/A | -146.36% | -86.13% |
Risk and Volatility
Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Duke Robotics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Mainz Biomed and Duke Robotics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
| Duke Robotics | 1 | 0 | 1 | 0 | 2.00 |
Duke Robotics has a consensus price target of $12.00, indicating a potential upside of 187.08%. Given Duke Robotics’ stronger consensus rating and higher possible upside, analysts clearly believe Duke Robotics is more favorable than Mainz Biomed.
Valuation and Earnings
This table compares Mainz Biomed and Duke Robotics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mainz Biomed | $659,935.00 | 14.00 | -$21.65 million | ($65.60) | -0.02 |
| Duke Robotics | $380,000.00 | 37.73 | -$1.24 million | ($0.67) | -6.24 |
Duke Robotics has lower revenue, but higher earnings than Mainz Biomed. Duke Robotics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Summary
Duke Robotics beats Mainz Biomed on 7 of the 10 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
About Duke Robotics
Duke Robotics Corp (Nasdaq: DUKR) is a Fort Lauderdale, Florida–based company that develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. On the civilian side, its Insulator Cleaning Drone (IC Drone) is a drone-enabled system for cleaning and monitoring high-voltage electric utility insulators, and its AEROTRACE platform uses AI-powered aerial monitoring to help infrastructure operators assess assets and prioritize maintenance. In defense, the company holds the intellectual property behind the Bird of Prey, a fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, which is marketed by Elbit Systems Land Ltd. under the brand name Bird of Prey (formerly known as TIKAD).
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
